Search - tctmd.com

Displaying 41 - 60 of 142

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for January 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2022

January 31, 2022

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

December 27, 2021

TCTMD’s Top 10 Most Popular Stories for October 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for October 2021

November 02, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Apixaban May Be Best DOAC for Frail, Older Patients With AF

News Daily News

Apixaban May Be Best DOAC for Frail, Older Patients With AF

July 19, 2021

Observational Study Supports Continuing Oral Anticoagulation During PCI

News Daily News

Observational Study Supports Continuing Oral Anticoagulation During PCI

Michael O'Riordan

April 06, 2021

DOACs Safe, Effective in Subset of Valvular AF Patients

News Daily News

DOACs Safe, Effective in Subset of Valvular AF Patients

March 31, 2021

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

News Conference News AHA 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

November 14, 2020

DOACs May Up Post-TAVR Survival in A-fib: OCEAN-TAVI

News Daily News

DOACs May Up Post-TAVR Survival in A-fib: OCEAN-TAVI

October 29, 2020

More Evidence of Lower Fracture Risk With DOACs Versus Warfarin

News Daily News

More Evidence of Lower Fracture Risk With DOACs Versus Warfarin

May 19, 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

News Conference News ACC 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

March 25, 2020

A ‘Virtual’ ACC 2020? TCTMD Has You Covered, However Things Roll Out

News Opinion Editor's Corner

A ‘Virtual’ ACC 2020? TCTMD Has You Covered, However Things Roll Out

March 16, 2020

Choosing a DOAC? Apixaban May Have an Edge Over Rivaroxaban

News Daily News

Choosing a DOAC? Apixaban May Have an Edge Over Rivaroxaban

March 09, 2020

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

News Daily News

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

February 28, 2020

No Stroke Reduction but Increased Bleeding With OAC in Dialysis Patients

News Daily News

No Stroke Reduction but Increased Bleeding With OAC in Dialysis Patients

January 21, 2020

News Daily News

FDA Approves Two Generic Versions of Apixaban

December 23, 2019

Switch Anticoagulants for A-fib Patients Needing a Stent? RE-DUAL PCI Insights

News Daily News

Switch Anticoagulants for A-fib Patients Needing a Stent? RE-DUAL PCI Insights

December 02, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.